MLC1 and HIV infectious disease: In the same case, in TE PLWH, 2-DR presented a lower risk of treatment discontinuation (hazard ratio [HR]: 0.74, 95% CI: 0.3 to 2.1, p = 0.56), adjusted by age, sex, rate of PLWH with HCV coinfection, CD4+ T-cell count (cells/μL) at study treatment initiation, time from diagnosis of HIV infection and years from first HIV treatment, rate of PLWH with VL<200 copies/mL at study treatment initiation, and number of previous regimen of ART.